Barber Allisa, Ramamurthi Aishu, Ebert Madeline, Rodriguez-Unda Nelson
Department of Plastic Surgery, Medical College of Wisconsin, Milwaukee, WI, 53212.
JPRAS Open. 2025 Apr 5;44:354-363. doi: 10.1016/j.jpra.2025.04.002. eCollection 2025 Jun.
Alloplastic breast reconstruction continues to be the most prevalent breast reconstruction performed in the United States. Plastic surgeons are challenged to recreate the breast footprint after the ablative surgeon's mastectomy. Mesh augmentation has emerged as a valuable tool in controlling implant migration. Several soft tissue support breast meshes have been introduced, each characterized by a different risk profile, cost, and associated complications.
This manuscript presents a comprehensive systematic review, with updated data over the last decade, of the use of a resorbable and less costly VICRYL (Ethicon, Somerville, NJ, USA) mesh in breast reconstruction after mastectomy.
The authors conducted a systematic review of the use of VICRYL mesh in breast reconstruction using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The authors queried five databases. Data was collected using a standardized form and underwent review using set inclusion and exclusion criteria. The primary outcome variable was reconstructive failure, with secondary outcomes including seroma, hematoma, skin necrosis, and infection.
A total of 693 articles were found after the multi database search. Forty articles met inclusion criteria. Following full text review, six articles analyzing 511patients were included. VICRYL mesh was utilized in 711 breast reconstructions, of which 5% were complicated by reconstructive failure (confidence interval (CI): 4.75-5.25%); 1.6% by seroma (CI: 1.53-1.67%); 3.33% by infection (CI: 3.14-3.52%); 1.83% by hematoma (CI: 1.71-1.95%); and 6.33% by skin necrosis (CI: 6.03-6.63%).
VICRYL mesh repeatedly demonstrates low reconstructive failure in breast reconstruction with an acceptable complication profile.
人工乳房重建仍然是美国最常见的乳房重建方式。整形外科医生面临的挑战是在切除性外科医生进行乳房切除术后重新塑造乳房外形。网片增大术已成为控制植入物移位的一种有价值的工具。几种软组织支撑乳房网片已被引入,每种网片都有不同的风险特征、成本和相关并发症。
本文献对过去十年中可吸收且成本较低的薇乔(美国新泽西州萨默维尔市的Ethicon公司生产)网片在乳房切除术后乳房重建中的应用进行了全面的系统评价,并更新了数据。
作者按照系统评价和Meta分析的首选报告项目(PRISMA)指南,对薇乔网片在乳房重建中的应用进行了系统评价。作者查询了五个数据库。使用标准化表格收集数据,并根据设定的纳入和排除标准进行审查。主要结局变量是重建失败,次要结局包括血清肿、血肿、皮肤坏死和感染。
经过多数据库搜索,共找到693篇文章。40篇文章符合纳入标准。经过全文审查,纳入了6篇分析511例患者的文章。薇乔网片用于711例乳房重建,其中5%发生重建失败并发症(置信区间(CI):4.75 - 5.25%);1.6%发生血清肿(CI:1.53 - 1.67%);3.33%发生感染(CI:3.14 - 3.52%);1.83%发生血肿(CI:1.71 - 1.95%);6.33%发生皮肤坏死(CI:6.03 - 6.63%)。
薇乔网片在乳房重建中反复显示出较低的重建失败率,且并发症情况可接受。